Amgen Cleared Again On Kanjinti As Trial Looms
Denial Of Preliminary Injunction Upheld On Appeal
With an infringement trial set to begin next month, Amgen can continue to sell its Kanjinti trastuzumab biosimilar in the US after a Court of Appeals shot down originator Genentech's latest bid to block sales of the rival to its Herceptin blockbuster.
